Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
119 articles
A Blood Test That Screens 50+ Cancers Moves Closer
A breakthrough blood test that screens for 50+ cancers is edging toward real-world use. This article breaks down what...
Moderna Some Approvals Ahead: Is the Stock a Buy?
Moderna’s growth story now centers on a broader mRNA pipeline and FDA decisions. This guide breaks down the upcoming ...
Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Parabilis Soared Biggest Biotech: Is It Too Late to Buy?
A record biotech IPO backdrop has investors buzzing about Parabilis Medicines. This guide breaks down what the surge ...
Is Viking Therapeutics Stock Going to $100? Key Signals
Viking Therapeutics sits at the intersection of biotech risk and big growth potential. This article breaks down what ...
Lilly Novo Nordisk Battle Intensifies as Obesity Drugs Surge
Eli Lilly's Q1 2026 results slam the lid on the GLP-1 duopoly's early calm, with Lilly’s revenue exploding and Novo N...
Prediction: Pfizer Stock Could Double If Pipeline Delivers
Pfizer stock is navigating a pivot from COVID-era revenues to a broader drug portfolio. Analysts weigh the odds of a ...
Zealand Pharma Loses Fifth of Value After Trial Dropouts
Danish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...
Investors Seek GLP-1 Alternatives After Nausea Hurdles
A new wave of weight-loss therapies aims to beat current GLP-1 drugs by reducing side effects and daily dosing. Inves...
Meet Biotech Stock That's Changing the Game in 2026
A smaller biotech is stealing headlines in 2026 by delivering strong trial results and strategic collaborations. This...
InspireMD NSPR 2026 Earnings: First Quarter Review
Investors are zooming in on InspireMD after its Q1 2026 earnings. This detailed look breaks down the numbers, the pro...